All Stories

  1. Data from Whole-Genome HPV Liquid Biopsy for HPV-Associated Cancer Detection and Viral Physical State Classification
  2. Supplementary Figure S1 from Whole-Genome HPV Liquid Biopsy for HPV-Associated Cancer Detection and Viral Physical State Classification
  3. Supplementary Table S1 from Whole-Genome HPV Liquid Biopsy for HPV-Associated Cancer Detection and Viral Physical State Classification
  4. Supplementary Table S2 from Whole-Genome HPV Liquid Biopsy for HPV-Associated Cancer Detection and Viral Physical State Classification
  5. Sensitivity to ATR–CHK1 pathway inhibition in MDS/AML is enhanced by SRSF2 mutations and reduced by RUNX1 loss
  6. Whole Genome HPV Liquid Biopsy for HPV-Associated Cancer Detection and Viral Physical State Classification
  7. Liquid Biopsy of HPV Cell-Free DNA Enables Blood-Based Early Detection and Molecular Stratification of HPV-Associated Cancer and Precancer Stages
  8. Human and Viral Whole-Genome Sequencing Reveals HPV-Driven Carcinogenesis and Mutational Signatures in Sinonasal Squamous Cell Carcinoma
  9. Supplementary Data from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
  10. Supplementary Figures from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
  11. Supplementary Tables from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
  12. Sensitivity to ATR-CHK1 pathway inhibition in AML/MDS is enhanced by SRSF2 mutations and reduced by RUNX1 loss
  13. Whole Exome Sequencing and Single-Cell DNA Sequencing for Assessment of Clonal Heterogeneity and Evolution in Acute Myeloid Leukemia
  14. Whole exome sequencing and single-cell DNA sequencing for assessment of clonal heterogeneity and evolution in acute myeloid leukemia
  15. Monosomy 7/del(7q) Cause Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia
  16. P-374 Stratifying multiple myeloma patients for personalized therapy based on TP53 mutation, deletion, and drug response profiles
  17. Monosomy 7/del(7q) Cause Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia
  18. Data from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
  19. Data from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
  20. Supplementary Data from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
  21. Supplementary Data from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
  22. Supplementary Figures from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
  23. Supplementary Figures from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
  24. Supplementary Tables from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
  25. Supplementary Tables from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
  26. Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
  27. Implementing a functional precision medicine tumor board for acute myeloid leukemia
  28. Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature
  29. Converging molecular evolution in acute myeloid leukaemia
  30. Molecular Basis of Mismatch Repair Protein Deficiency in Tumors from Lynch Suspected Cases with Negative Germline Test Results
  31. Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease
  32. Does breast carcinoma belong to the Lynch syndrome tumor spectrum? – Somatic mutational profiles vs. ovarian and colorectal carcinomas
  33. Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia
  34. Somatic mutations and T-cell clonality in patients with immunodeficiency
  35. Somatic Mutations in Clonally Expanded T-lymphocytes in Patients with Chronic Graft-Versus-Host Disease
  36. Abstract 2945: Clinical implementation of precision systems oncology in the treatment of ovarian cancer based on ex-vivo drug testing and molecular profiling
  37. Epidemiological, clinical and molecular characterization of Lynch‐like syndrome: A population‐based study
  38. Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia
  39. Somatic Mutations in CD8+ T Cells in Patients with Chronic Immune Thrombocytopenia Are Associated with Increased Clonality and Cytotoxic Phenotype of CD8+ T Cells
  40. Somatic Mutations in T Cells As Possible Regulators of Immunodeficiency
  41. Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells
  42. Converging endometrial and ovarian tumorigenesis in Lynch syndrome: Shared origin of synchronous carcinomas
  43. Abstract 2199: Establishment and high-throughput drug testing of multiple patient-derived cells from each renal cancer; intratumor heterogeneity of drug response and implications for precision medicine
  44. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
  45. Sequencing of Lynch syndrome tumors reveals the importance of epigenetic alterations
  46. 3Precision systems medicine in urological Tumors – Molecular profiling and functional testing
  47. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling
  48. Abstract 410: Identifying ovarian cancer specific targeted drugs using high-throughput drug sensitivity profiles of primary cancer cells
  49. Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis
  50. Identification of precision treatment strategies for relapsed/ refractory multiple myeloma by functional drug sensitivity testing
  51. Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer
  52. Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
  53. Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia
  54. High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia
  55. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia
  56. Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia
  57. Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer
  58. A6.02 Somatic mutations in clonally expanded CD8+T cells in patients with newly diagnosed rheumatoid arthritis
  59. Rad51c- and Trp53-double-mutant mouse model reveals common features of homologous recombination-deficient breast cancers
  60. Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia
  61. Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3
  62. Novel TBL1XR1, EPHA7 and SLFN12 mutations in a Sezary syndrome patient discovered by whole exome sequencing
  63. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia
  64. Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation
  65. Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia
  66. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia
  67. SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia
  68. Comparison of solution-based exome capture methods for next generation sequencing